LTI-01 is under clinical development by Lung Therapeutics and currently in Phase II for Pleural Effusion. According to GlobalData, Phase II drugs for Pleural Effusion have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LTI-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LTI-01 overview

LTI-01 is under development for the treatment of loculated pleural effusions and empyema. It is administered through intrapleural route. It is a proenzyme or zymogen and becomes activated in the pleural space. The therapeutic candidate is a new molecular entity.

Lung Therapeutics overview

Lung Therapeutics is a pharmaceutical company that offers orphan drug indications for lung injury and diseases. The company provides service to underserved, life-threatening lung condition. Its pipeline candidates include LTI-01, a single chain urokinase plasminogen activator (scuPA), which is used for clearance of fibrinous scar tissue in patients with loculated pleural effusion and LTI-03, a drug product for the treatment of Idiopathic Pulmonary Fibrosis. The company aims to create better pharmaceutical treatment options for IPF, LPE, and other underserved lung conditions. Lung Therapeutics is headquartered in Austin, Texas, the US.

For a complete picture of LTI-01’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.